AR101 Real-World Open-Label Extension Study

Completed · Phase 3

Conditions studied: Peanut Allergy

In brief

This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.

Key facts

Study ID
NCT03337542
Run by
Aimmune Therapeutics, Inc.
People needed
243
Starts
2017-10-18
Expected to finish
2019-09-20
Last updated by the study team
2021-11-02

Who can join

Age: 4 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.